Skip to main content

Table 4 Utility decrements and cycle rates of adverse events

From: Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden

 

Utility decrements

Cycle rates (%)

Ustekinumab [23,24,25]

Adalimumab [40, 41, 48, 51, 52]

Vedolizumab [39, 53]

Serious infection

− 0.52 [54]

0.34

0.32

0.32

Tuberculosis

− 0.55 [55]

0.00

0.00

0.00

Lymphoma

− 0.20 [56]

0.00

0.00

0.00

Hypersensitivity

− 0.11 [57]

0.01

0.00

0.00

Skin reactions

− 0.03 [58]

0.75

10.37

0.59